21 completed, 14 recruiting, 7 unknown, 6 terminated. 29 Phase 2, 25 Phase 1, 15 Not applicable, 4 Phase 3, 1 Phase 4.
Follow Clinical Trials, Phase II as Topic: new trials by email Literature Review of Clinical Trials, Phase II as Topic trials Research Report on Clinical Trials, Phase II as Topic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Design, Development and Evaluation of a Digital Health Assistant for Paediatric Asthma Phase I (months 1-3): DHA core functionality, Phase II (months 3-6): platform augmentation, Embedded qualitative study - Paediatric Asthma | Not yet recruiting | University Children's Hospital Basel | 42 | 2026-04-01 | 2026-03-16 | |
| Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants CNS Stimulant, Placebo, CNS Stimulant open label first phase - ADHD - Attention Deficit Disorder With Hyperactivity, Irritability | Phase 4 | Recruiting | Milton S. Hershey Medical Center | 136 | 2026-03-05 | 2026-04-20 |
| A Study to Evaluate Safety, PK and Efficacy of GH55 in Combination With GH21 in Patients With Solid Tumors Phase I dose escalation, Phase I: Dose Expansion, phase II - Advanced Solid Tumor Cancer | Phase 1 / Phase 2 | Not yet recruiting | Suzhou Genhouse Bio Co., Ltd. | 152 | 2026-02-24 | 2026-03-03 |
| Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) LNTH2403 Phase 1 dose, Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). - Relapsed / Refractory Osteosarcoma | Phase 1 / Phase 2 | Recruiting | Lantheus Medical Imaging | 55 | 2026-02-03 | 2026-05-01 |
| Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors SA53-OS (phase 1), SA53-OS (phase 2) - Solid Tumor | Phase 1 / Phase 2 | Recruiting | Lamassu Bio Inc | 70 | 2025-03-10 | 2026-09-09 |
| Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC Adebrelimab + paclitaxel/nab-paclitaxel + cisplatin followed by chemoradiotherapy, chemoradiotherapy followed by adebrelimab + paclitaxel/nab-paclitaxel + cisplatin, TNT treatment [TNT group one (phase 2) or TNT group two (phase 2)] - Esophageal Squamous Cell Carcinoma (ESCC) | Phase 2 / Phase 3 | Not yet recruiting | YIN LI | 474 | 2025-03-01 | 2025-03-11 |
| A Study of GQ1010 in Subjects With Advanced Solid Tumors Dose Escalation, Dose Expansion1, Dose Expansion2 - Advanced Malignant Solid Tumors | Phase 1 / Phase 2 | Recruiting | GeneQuantum Healthcare (Suzhou) Co., Ltd. | 260 | 2024-05-23 | 2025-02-10 |
| Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma Tislelizumab combined with two predefined dose groups of palbociclib, RP2D dose Of Tislelizumab combined with palbociclib was selected for phase II clinical trial. - Bladder Cancer | Phase 1 / Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 36 | 2024-05-15 | 2025-08-11 |
| Oral Proprioceptive Sensitivity and Upper Limb Kinesthetic Acuity: A Pilot Study Upper-Limb Kinesthetic Acuity Assessment, Effect of Auditory Stimulation on Visual Perception, Oral Proprioceptive Sensitivity Assessment - Oral Proprioceptive Sensitivity and Upper Limb Kinesthetic Acuity | Completed | Sophie Román Richon | 33 | 2024-01-14 | 2026-10-02 | |
| CRISOL Mente: A Multilevel Community Intervention to Reduce Mental Health Disparities Among Latinos Outreach/navigator, Auxiliary to care, Stepped care and task shifting - Depression, Unipolar, Anxiety Disorders | Not applicable | Active not recruiting | Drexel University | 603 | 2023-11-10 | 2026-04-15 |
| A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i 600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib, RP2D dose of 600mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial. - Inhibition of Autophagy Synergizes Anti-tumor Effect | Phase 1 / Phase 2 | Recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 29 | 2023-11-07 | 2024-12-03 |
| JUMP_START - Optimization of Care for Young Cancer Patients with Gastrointestinal Tumors No intervention, Tailored counseling programs (Phase 2) - Gastrointestinal Cancer | Recruiting | University Hospital Heidelberg | 250 | 2023-10-01 | 2024-10-15 | |
| Diabetes Inspired Culinary Education (DICE): Culinary Medicine Intervention for At-Risk Youth With Type 1 Diabetes Diabetes Inspired Culinary Education (DICE) - Phase 1, Diabetes Inspired Culinary Education (DICE) - Phase 2 - Type 1 Diabetes | Not applicable | Active not recruiting | Case Western Reserve University | 32 | 2023-09-01 | 2025-12-22 |
| Pembrolizumab and ADG106 in Advanced Solid Cancers and Triple Negative Breast Cancer Pembrolizumab & ADG106 (Phase Ib), Pembrolizumab & ADG106 (Phase II) - Advanced Solid Tumor, Triple Negative Breast Cancer | Phase 1 / Phase 2 | Recruiting | National University Hospital, Singapore | 51 | 2023-06-12 | 2025-07-25 |
| The Effects of Bilateral and Unilateral Perceptual-Motor Exercises on Manual Dexterity and Visuospatial Memory in Children With Nonverbal Learning Disorder Unilateral perceptual-motor (PM) training intervention followed by free-play activities, Free-play activities followed by unilateral perceptual-motor (PM) training intervention, Bilateral perceptual-motor (PM) training intervention followed by free-play and non-interventional activities in Phase 2 - Non-verbal Learning Disorder | Not applicable | Completed | Allameh Tabatabai University | 20 | 2023-05-01 | 2026-02-17 |
| Study of the Effect of Proprioceptive Stimuli in the Stomatognathic Area on Visual Perception, With and Without Sound Baseline Condition (No Stimuli), Auditory Stimulation only, Auditory and Oral Proprioceptive Stimulation (OPS) - Proprioception, Visual Perception | Completed | Sophie Román Richon | 38 | 2022-12-16 | 2025-07-04 | |
| Comprehensive Adaptive Multisite Prevention of University Student Suicide Treatment As Usual (TAU), Collaborative Assessment and Management of Suicidality (CAMS) - Phase 1, Dialectical Behavior Therapy (DBT) - Phase 2 - Suicide | Not applicable | Completed | Duke University | 253 | 2022-10-25 | 2026-08-19 |
| Dual Anti-CD22/CD19 Chimeric Antigen Receptor-directed T Cells (CART2219.1) for Relapsed Refractory B-Lineage Leukaemia Phase I, Phase II - Lymphoblastic Leukemia, Lymphoblastic Leukemia, Acute, Childhood | Phase 1 / Phase 2 | Unknown | KK Women's and Children's Hospital | 48 | 2022-07-18 | 2023-03-09 |
| A Phase Ib/II Study of Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection in Chinese Participants With Acute Gout Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 100 mg (phase Ib), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 200 mg (phase Ib), Recombinant Anti-IL-1β Humanized Monoclonal Antibody Injection 300 mg (phase Ib) - Acute Gout | Phase 1 / Phase 2 | Unknown | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 120 | 2022-06-29 | 2022-10-20 |
| Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity Phase 2; Low Dose MYOBLOC (10,000 Units), Phase 2; High Dose MYOBLOC (20,000 Units), Phase 2; Placebo - Spasticity, Cerebrovascular Accident | Phase 2 / Phase 3 | Terminated | Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC | 32 | 2021-11-02 | 2026-05-27 |
Showing 20 of 55. Sign in to see all of them.
Breast Neoplasms (6) · Prostatic Neoplasms (3) · Stroke (3) · Triple Negative Breast Neoplasms (3) · Brain Injuries, Traumatic (2) · Carcinoma, Non-Small-Cell Lung (2) · Hemiplegia (2) · Muscle Spasticity (2) · Neoplasm Metastasis (2) · Obesity (2) · Pain (2) · Recurrence (2) · Urinary Bladder Neoplasms (2) · Acute Lung Injury (1) · Acute Pain (1)
Brigham and Women's Hospital (2) · Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC (2) · Sophie Román Richon (2) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (2) · ANRS, Emerging Infectious Diseases (1) · Abramson Cancer Center at Penn Medicine (1) · Allameh Tabatabai University (1) · Aragon Pharmaceuticals, Inc. (1) · AtlasMedx, Incorporated (1) · Case Western Reserve University (1) · Centre Hospitalier Universitaire Dijon (1) · Chinese Academy of Medical Sciences (1) · Ciusss de L'Est de l'Île de Montréal (1) · Drexel University (1) · Duke University (1)
United States (23) · China (8) · France (7) · Spain (5) · Germany (3) · Italy (3) · Canada (2) · Hungary (2) · Poland (2) · Singapore (2) · South Korea (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Iran (1)
Joseph T Hull, PhD (2) · Axel Wolf, RN, PhD, Professor (1) · Brad Hennessie, MHA, MBA (1) · Catherine R McManus, PhD, RDN, LD (1) · Christine Tosone, Ms, RAC (1) · Daniel Pollyea, MD (1) · David Kozono, MD, PhD (1) · David Porter, MD (1) · Diana J. Wilkie, PhD (1) · Edgar Delgado-Eckert, Prof. Dr. med. (1) · Fermin Labayen Beraza, MD (1) · Filipe Da Conceicao Barata (1) · Gabi Hanna, MD (1) · Hejian Zou, MD (1)
PMID 10801169, PMID 15733657, PMID 17977860, PMID 18612266, PMID 20042440, PMID 20158132, PMID 22456662, PMID 22784116, PMID 25232716, PMID 26492629, PMID 27160947, PMID 28633425, PMID 29438373, PMID 30627694, PMID 31308621, PMID 31889999, PMID 32103890, PMID 33207944, PMID 34965951, PMID 34998048, PMID 35046060, PMID 35366825, PMID 36598770, PMID 37650981, PMID 37678374, PMID 38950555, PMID 38978605, PMID 39540213, PMID 39731909, PMID 40204996, PMID 40262131, PMID 40371564, PMID 40579407, PMID 41140451, PMID 41462280, PMID 41747920, PMID 41805550, PMID 9779724
2017 (2), 2015 (1), 2016 (1), 2019 (1), P01GM116691 (1), R01DK031127 (1), R01HL078536 (1), R01MH104235 (1), R01MH116050 (1), R01MH116052 (1), R01MH116061 (1), R01MH116062 (1)